There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Verrica Pharmaceuticals (VRCA – Research Report) and Intercept Pharma (ICPT – Research Report) with bullish sentiments.
Verrica Pharmaceuticals (VRCA)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Verrica Pharmaceuticals, with a price target of $17.00. The company’s shares closed last Monday at $14.07.
According to TipRanks.com, Belanger is a 5-star analyst with an average return of 11.1% and a 48.1% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.
Currently, the analyst consensus on Verrica Pharmaceuticals is a Strong Buy with an average price target of $20.67, a 42.5% upside from current levels. In a report issued on June 24, Northland Securities also initiated coverage with a Buy rating on the stock with a $21.00 price target.
Intercept Pharma (ICPT)
In a report released today, Michael Morabito from Chardan Capital reiterated a Buy rating on Intercept Pharma, with a price target of $105.00. The company’s shares closed last Monday at $46.70, close to its 52-week low of $44.50.
According to TipRanks.com, Morabito is ranked #5756 out of 6723 analysts.
Intercept Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $73.59, a 55.7% upside from current levels. In a report issued on June 23, RBC Capital also maintained a Buy rating on the stock with a $117.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.